Alvotech has given Japanese firm Fuji Pharma exclusive commercial rights to its biosimilars portfolio in Japan. Under the deal, Alvotech will be responsible for developing and supplying biosimilars within its pipeline that currently includes rivals to AbbVie’s Humira (adalimumab) and Janssen’s Stelara (ustekinumab), the latter using perfusion fermentation technology.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?